You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
Milenia will exclusively offer the test to patients through its network of 12 diagnostic centers in Mexico, and will also make future assays available.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.